neoadjuvant
No description yet: the sentence for this tag has not been written. 11 records carry it: 11 people.
Related tags
11 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Andrea Necchi Head of Genitourinary Medical Oncology, IRCCS San Raffaele Hospital; Professor, Vita-Salute San Raffaele University · IRCCS Ospedale San Raffaele Led PURE-01, the first neoadjuvant pembrolizumab trial in bladder cancer, and now leads bladder-preserving immunotherapy studies. | Bladder & urothelial cancer | none | urothelial, italy | ||
Georgina V. Long Co-Medical Director, Melanoma Institute Australia; Chair of Melanoma Medical Oncology and Translational Research, University of Sydney · Melanoma Institute Australia Melanoma trialist who led COMBI-d, COMBI-AD and NADINA, moving immunotherapy before surgery for stage III disease. | Melanoma | none | melanoma, australia | ||
Jennifer A. Wargo Professor of Genomic Medicine and Surgical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Surgeon-scientist who showed the gut microbiome shapes response to immunotherapy and led early neoadjuvant melanoma trials. | Melanoma | none | melanoma, microbiome | ||
Jonathan Spicer Thoracic Surgeon and Associate Professor of Surgery, McGill University Health Centre · Rosalind and Morris Goodman Cancer Institute, McGill University The surgeon on CheckMate 816 who showed neoadjuvant immunotherapy does not make lung cancer operations harder. | Non-small-cell lung cancer | none | lung, surgery | ||
Luca Gianni Medical oncologist and President, Fondazione Michelangelo, Milan · Fondazione Michelangelo Milan oncologist who led NeoSphere, the trial that showed adding pertuzumab to trastuzumab and docetaxel before surgery clears more HER2-positive breast cancers, the basis for pertuzumab's neoadjuvant approval. | Early HER2-positive breast cancer, HER2-positive breast cancer | none | breast, trialist | ||
Marc G. Besselink Professor of Pancreatic and Hepatobiliary Surgery, Amsterdam UMC · Amsterdam UMC / Cancer Center Amsterdam Dutch surgeon who leads the PREOPANC trials testing chemotherapy or chemoradiation before pancreatic cancer surgery. | Pancreatic ductal adenocarcinoma | none | pancreatic, surgery | ||
Maria E. Cabanillas Professor of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center · MD Anderson Cancer Center Turned anaplastic thyroid cancer from a death sentence into a treatable disease with BRAF-targeted therapy and neoadjuvant strategies. | Thyroid cancer | none | thyroid, braf | ||
Ravindra Uppaluri Chief of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital and Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Surgeon-scientist who led the first neoadjuvant pembrolizumab trial in head and neck cancer and the KEYNOTE-689 study that made it standard. | Head and neck squamous cell carcinoma | none | head-and-neck, surgery | ||
Sapna P. Patel Professor of Medicine and Director of Melanoma Medical Oncology, University of Colorado Cancer Center · University of Colorado Cancer Center Led SWOG S1801, the trial that showed giving pembrolizumab before surgery, not just after, improves outcomes in melanoma. | Melanoma, Uveal melanoma | none | melanoma, swog | ||
Timothy F. Cloughesy Director, UCLA Neuro-Oncology Program · UCLA Jonsson Comprehensive Cancer Center Neuro-oncologist whose neoadjuvant PD-1 trial showed immunotherapy before surgery can activate immune responses in glioblastoma. | Glioma & glioblastoma | none | glioma, immunotherapy | ||
Tina Cascone Associate Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Led CheckMate 77T, one of the perioperative immunotherapy trials that changed how operable lung cancer is treated. | Non-small-cell lung cancer | none | lung, immunotherapy |